Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn

Clicks: 469
ID: 120562
1997
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #18 of 581 articles by views in pediatrics

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 581 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth (< or = 35 wee …
Reference Key
1997pediatricsrespiratory Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;
Journal pediatrics
Year 1997
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.